Purification of acid sphingomyelinase from human placenta: Characterization and N-terminal sequence  by Lansmann, Stephanie et al.
FI:BS 17937 FEBS Letters 399 (1996) 227 231 
Purification of acid sphingomyelinase from human placenta: 
Characterization and N-terminal sequence 
Stephanie Lansmann a, Klaus Ferlinz% Robert Hurwitz b, Oliver Bartelsen a, 
Gereon Glombitza , Konrad Sandhoff a,* 
'ffnstitut fiir Organische Chemie und Biochemie, Universitgit Bonn, Gerhard-Domagk-Str. 1, D-53121 Bonn, Germany 
blnstitut fiir Physiologische Chemie, Universit~it Bonn, Gerhard-Domagk-Str. 1, D-53121 Bonn, Germany 
Received 3 October 1996; revised version received 6 November 1996 
Al~stract Human placental acid sphingomyelinase (ASM) was 
purified by sequential chromatography on Con A-Sepharose, 
octyI-Sepharose and Matrex gel red A. Final purification to 
apparent homogeneity was achieved by immunoaff'mity chroma- 
tography employing polyclonal anti-ASM antibodies. The 
antibodies also allowed specific detection of ASM by Western 
blotting at various stages of purification. The ASM activity was 
enriched about ll0000-fold over that of the crude extract, 
yielding an enzyme preparation with a specific activity of about 
1 mmol/h per mg protein in a detergent-containing assay system. 
Analysis of the final preparation by SDS-PAGE resulted in a 
single protein band with a molecular mass of ~ 75 kDa, which 
was reduced to ,-~60 kDa after complete deglycosylation. 
Microsequencing of the purified ASM revealed the N-terminal 
amino acid sequence of the mature placental enzyme. 
l~.y words': Mature acid sphingomyelinase; Human placenta; 
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1 Introduction 
Acid sphingomyelinase (ASM) is a lysosomal enzyme cata- 
15 zing the hydrolysis of sphingomyelin to ceramide and phos- 
p lorylcholine. An inherited ASM deficiency results in type A 
a ld B Niemann-Pick disease (NPD), an autosomal-recessive 
li~id storage disorder accompanied by massive accumulation 
e" sphingomyelin lysosomes [1,2]. 
Different purification procedures from human placenta, 
b'ain and urine led to final ASM preparations of different 
nolecular masses (30-90 kDa) with specific activities in the 
r~mge of 60 800 ~tmol h 1 mg-a [3-6]. In 1987 we succeeded 
i~ isolating ASM from human urine [7]. The enzyme was 
s:aown to be a monomeric ,~72 kDa glycoprotein with a 
sl~ecific activity of ,~ 2.5 mmol h -1 mg -1 in a detergent-con- 
t~dning assay system. The purified ASM also hydrolysed phos- 
ptaatidylcholine and phosphatidylglycerol in a phospholipase 
(- l ike manner [7], consistent with previous findings [8--11]. 
Several alternatively spliced human ASM cDNAs were iso- 
Lted and the genomic sequence ncoding ASM was charac- 
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terized [12-14]. Recently, ASM-deficient mice have been gen- 
erated, thus, providing an animal model for NPD [15,16]. 
Special interest has focused on the role of ceramide and its 
metabolites in signal transduction, apoptosis, cell differentia- 
tion and proliferation. Recent studies have shown that besides 
a neutral membrane-associated sphingomyelinase, a lysosomal 
ASM plays an important role in TNF-a- and Fas-induced 
activation of the sphingomyelin cycle [17,18]. 
We recently described the production of polyclonal rabbit 
and goat-anti-ASM antisera raised against recombinant ASM 
expressed in E. coli [19,20]. The anti-ASM antibodies were 
used successfully for studies on the biosynthesis and process- 
ing of ASM in human fibroblasts and transfected COS cells, 
revealing distinct post-translational processing during trans- 
port to the lysosomes [19,20]. ASM is synthesized as a 75 
kDa propolypeptide which is converted to a 72 kDa precursor 
in the ER/Golgi complex. The 72 kDa precursor form is proc- 
essed to the mature lysosomal 70 kDa form in the endoso- 
mal/lysosomal compartments. However, a small and variable 
amount of the ASM precursor is already processed in the ER/ 
Golgi compartments, yielding an enzymatically active 57 kDa 
form [201 . 
In order to gain more insight into the processing events of 
human ASM, we intended to establish an efficient procedure 
for the purification of ASM from readily available human 
placenta. As a result of the high enrichment achieved by the 
presented immunoaffinity purification, this procedure might 
be suitable for ASM purification from many other normal 
and pathological tissues (enzymatically less or non-active Nie- 
mann-Pick tissue). Isolation of pure N-terminally unblocked 
enzyme allowed, for the first time, sequencing of the N-ter- 
minal amino acids of human mature ASM, which originates 
from an N-terminally extended precursor protein by proteo- 
lytic processing. 
2. Materials and methods 
2.1. Materials 
Con A- and octyl-Sepharose CL-4B were purchased from Sigma, 
Affi-Gel Hz from Bio-Rad and Matrex gel red A and Centricon 30 
concentrators f om Amicon. Peptide-N-glycanase F and Endo H were 
obtained from Boehringer Mannheim. Molecular weight standards 
were supplied by Amersham. PVDF membrane was provided by Ma- 
cherey-Nagel and secondary antibody-alkaline phosphatase conju- 
gates by Dianova. All other reagents were of analytical purity. 
The following chromatographic steps were carried out at 4°C using 
a flow rate of 30 ml/h unless stated otherwise. All buffers contained 
0.02% (w/v) NaN3 as preservative. 
2.2. Antibody purification and preparation of the immunoaffinity matrix 
Anti-ASM immunoglobulins (IgG) were purified from polyclonal 
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goat-anti-ASM antiserum by combined (NH4)2SO4 precipitation and 
anion exchange chromatography as described [21]. The N-glycan of 
the purified IgG (10-15 rng/ml) was oxidized in the presence of 60 
mM NaIO,i in 0.1 M sodium acetate buffer, pH 5.5 (buffer A) for 45 
min at room temperature. Excess NaIO4 was removed by passing the 
IgG solution over a desalting column (10DG, Bio-Rad). For antibody 
immobilization, oxidized IgGs were added to the Affi-Gel hydrazide 
beads (8 10 mg IgG/ml gel) previously equilibrated with buffer A and 
the IgG/gel slurry rotated for 8 h at room temperature. Uncoupled 
IgGs were removed with 10 bed volumes of buffer A, followed by 20 
bed volumes of 1 M NaCI in PBS (buffer B). In order to enable 
elution under acid conditions (pH < 3), the hydrazone groups were 
reduced selectively with 15 mM NaBH3CN in 20 mM sodium phos- 
phate buffer, pH 6.5 for 2.5 h at room temperature. After washing 
with the incubation buffer the immunoaffinity column (1 x2 cm) was 
rinsed with 5 bed volumes of elution reagent (100 mM acetic acid 
containing 0.15% (w/v) OG) at a flow rate of 25 ml/h followed by 
buffer B at room temperature. The gel was stored at 4°C until use. 
2.3. ASM and protein assays 
Phospholipase C activity was measured with sphingomyelin and 
phosphatidylcholine as substrates, both 3H-labeled in the choline moi- 
ety as previously described [7]. Protein was quantified by the BCA 
method [22] using bovine serum albumin as standard. 
2.4. Digestion with glycosidases 
After heating for 5 min at 95°C in 0.5% SDS, the purified enzyme 
(~20 ng) was digested with Peptide-N-glycanase F (30 mU) and 
Endo H (2 mU) for 20 h at 37°C in 25 mM sodium phosphate buffer, 
pH 7.2 containing 50 mM EDTA and 50 mM sodium acetate buffer, 
pH 5, respectively, in the presence of a 5-fold excess of OG over SDS. 
2.5. SDS-PAGE and Western blotting 
Denaturing SDS-PAGE was performed on 10% polyacrylamide g ls 
according to Sch~igger and Von Jagow [23]. After SDS-PAGE, the 
proteins were electrophoretically transferred onto PVDF membrane 
using 50 mM borate buffer, pH 9, containing 15% (v/v) MeOH. The 
membrane was blocked for 1 h at 45°C with 2% (w/v) polyvinylpyr- 
rolidone K90 in PBS. ASM was detected with polyclonal rabbit or 
goat-anti-ASM antiserum (dilution 1:1000) using anti-rabbit or anti- 
goat IgG alkaline phosphatase conjugate, with NBT and BCIP as 
substrates. 
2.6. ASM purification from human placenta 
Human placentae (stored for 1-2 days at 4°C) were collected from a 
local hospital and immediately after delivery frozen at -70°C for 2-6 
months until use. 
2.6.1. Homogenization and (NH4)2S04 precipitation. Human pla- 
centae (1.5 kg), freed of cord, membranes and adipose tissue, were 
sliced into small pieces and homogenized for 1 min in a Waring 
blender in 1.5 1 of ice-cold 30 mM Tris-HC1, pH 7.2 (buffer C). 
Complete extraction was achieved by treating the mixture with an 
Ultra Turrax in the presence of 0.25% (w/v) NP-40. After centrifuga- 
tion (1 h, 17 700Xg), the supernatant (crude extract) was subjected to 
3060% (NH4)2SO4 fractionation. The precipitate was dissolved in 
600 ml of buffer C, containing 0.5 M NaCI, 0.1% (w/v) NP-40, 
I mM Ca/Mg/MnCI2 and 1 gM leupeptin (buffer D). 
2.6.2. Con A-Sepharose chromatography. After centrifugation (30 
min, 235000xg) and filtration (0.2 gm), the solubilized precipitate 
was applied to a Con A-Sepharose column (2.6 x 30 cm) equilibrated 
with buffer D. Unbound proteins were removed with 10 bed volumes 
of buffer D and bound glycoproteins eluted in the reverse direction at 
room temperature with a linear gradient of 0-20% (w/v) c~-D-methyl- 
glucopyranoside in buffer D. 
2.6.3. Octyl-Sepharose chromatography. Pooled fractions of the 
Con A-Sepharose luate with the highest specific ASM activity were 
loaded onto an octyl-Sepharose column (2.6x30 cm) equilibrated 
with buffer C. After washing with 0.01% NP-40 in buffer C, bound 
proteins were eluted in the reverse direction using a linear gradient of 
0.0l 1.5"/o (w/v) NP-40 in buffer C. 
2.6.4. Matrex gel red A chromatography. Pooled fractions of the 
octyl-Sepharose eluate containing the highest specific ASM activity 
were loaded onto a Matrex gel red A column ( l .6x 12 cm) equili- 
brated with buffer C containing 0.1% (w/v) NP-40 (buffer E). After 
washing, bound proteins were eluted in the reverse direction with a 
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linear gradient of 0~1.5 M NaCI in buffer E. 
2.6.5. Immunoaffinity chromatography. Pooled fractions of the 
Matrex gel red A eluate with the highest specific ASM activity were 
dialyzed against buffer E and applied to the immunoaffinity column 
(1 x 2 cm) equilibrated with buffer E (1 ml eluate/100 gl gel; flow rate, 
2 ml/h). For binding ~ 20 gg enzyme, 1 ml gel (~  6 mg IgG/ml gel) 
was sufficient. Non-specifically bound proteins were removed by se- 
quential washing with 10 bed volumes of buffer E, 20 bed volumes of 
buffer B containing 0.1% (w/v) NP-40 and 5 bed volumes of buffer A 
containing 0.15% (w/v) OG. ASM was eluted under batch conditions 
by incubating the immunoaffinity gel twice with elution reagent (cf. 
Section 2.2) for 2 min each at room temperature (100 gl gel/2x400 gl 
elution reagent). The eluate was removed and adjusted to pH 5 by 
adding 3 M sodium acetate buffer, pH 7.5. It was concentrated using 
Centricon 30 (Amicon) and the buffer was exchanged with 0.15°/,, (w/ 
v) OG in 10 mM Tris-HC1, pH 7.2. The concentrated nzyme (~25 
gg/ml) was stored in aliquots at -20°C. 
2. Z N-terminal amino acid sequenc&g 
Following SDS-PAGE, the purified ASM was electroblotted onto 
PVDF membrane and stained with Coomassie blue R250 according to 
Matsudaira [24]. The stained protein band was excised and its N- 
terminal sequence determined using a Beckman Sequencer (Porton 
3600) with an on-line phenylthiohydantoin analyser (System Gold, 
Beckman). 
3. Results 
3.1. Purification of  ASMfrom human placenta 
Table 1 summarizes the results of a typical purification of 
ASM from human placenta. Sequential chromatography on 
Con A-Sepharose, octyl-Sepharose and Matrex gel red A re- 
sulted in a ,~ 2400-fold enrichment of activity over the crude 
extract with a recovery of ,'~ 15%. An apparently pure ASM 
was obtained after additional immunoaffinity purification em- 
ploying polyclonal ant i -ASM antibodies raised against recom- 
binant ASM. The final enzyme preparation was enriched 
,~ l l0000-fo ld and had a specific activity of ,~1 mmol  h 1 
1 2 
kDa 
- -  220  
- -  97  
. . . .  65  
i -  46  
- -  30  
~ ~i-- 21 
Fig. 1. SDS-PAGE of purified ASM from human placenta. Purified 
ASM was subjected to SDS-PAGE (10% polyacrylamide) under 
non-reducing conditions. Protein bands were silver stained. The ar- 
row marks the position of the mature lysosomal ASM, Lanes: (1) 
purified ASM (0.25 gg); (2) molecular mass standards (0.2 gg/ 
band), myosin (220 kDa), phosphorylase b (97 kDa), bovine serum 
albumin (66 kDa), ovalbumin (46 kDa), carbonic anhydrase (30 
kDa) and trypsin inhibitor (21 kDa). 
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l ig. 2. Western analysis of purified ASM. Purified ASM was treated 
v.ith peptide-N-glycanase F or Endo H. Following non-reducing 
i3% SDS-PAGE, the enzyme was transferred onto PVDF mem- 
I.rane. ASM was detected using polyclonal rabbit-anti-ASM antiser- 
lm (dilution 1:2000). Lanes: (1) purified ASM, peptide-N-glycanase 
l-treated; (2) purified ASM, (3) purified ASM, Endo H-treated 
I XSM/lane: ~ 20 ng, each). 
~ ag-l. Both values are higher than those described in previous 
~eports on the placental enzyme [5,25]. 
As a consequence of the high enrichment achieved by the 
inclusion of immunoaffinity chromatography, this efficient 
tep in combination with the conventional chromatographic 
,teps first resulted in the isolation of pure placental ASM. 
itowever, the immunoaffinity step was accompanied by low 
, :nzyme recovery, presumably due to reduced affinity of the 
tnti-ASM IgGs covalently linked to the gel matrix. The pre- 
)aration of the immunoaffinity gel involved oxidation of the 
i gG N-glycan with NaIO4 to enable IgG coupling to the Affi- 
Gel hydrazide beads and reduction of the resulting hydrazone 
)onds with NaCNBH3, necessary for elution under acid con- 
litions. In addition, the harsh washing and elution conditions 
,nay have contributed to loss of enzyme activity. Even in the 
)ptimized elution reagent used (100 mM acetic acid contain- 
ng 0.15% (w/v) OG) the enzyme was quite labile. After only 5 
ind 10 min of incubation i  the elution reagent, ASM activity 
~as decreased by ~ 30 and ,~ 50%, respectively. The antigen 
zas therefore luted batchwise and the elution time minimized 
o 2 × 2 min, allowing maximal release of bound ASM with 
:he highest possible recovery of activity. 
3.2. Properties and N-terminal sequence 
SDS-PAGE of the purified placental ASM (,-~ 0.25 gg) un- 
der reducing (not shown), as well as under non-reducing con- 
ditions, followed by silver staining, revealed a single protein 
band with an apparent molecular mass of 75 kDa (Fig. 1). No 
significant contamination was detected by this method, indi- 
cating that this preparation was more than 95% pure. Micro- 
sequencing of the isolated enzyme (,-~ 4 gg) revealed the N- 
terminal amino acid sequence of mature lysosomal ASM 
(H2N-GlySa-Trp-Gly-Asn-Leu-Thr-Cys-Pro-...), which aligns 
with residues 83-90 of the amino acid sequence of the ASM 
precursor derived from the ASM cDNA. 
For oligosaccharide side chain analysis, the pure enzyme 
was either treated with peptide-N-glycanase F or with Endo 
H and subjected to SDS-PAGE and Western blotting (Fig. 2). 
Completely deglycosylated enzyme was immunodetected at 
,~ 60 kDa and Endo H-treated ASM at 64-66 kDa in accor- 
dance with the results in previous reports on urinary and 
fibroblast ASM [7,19]. 
Western analysis of ASM (,~20 ng) at different stages of 
purification using rabbit or goat-anti-ASM antiserum (1:1000) 
showed one significant band at ,~ 75 kDa (Figs. 2 and 3). In 
addition, a faint band at ~ 57 kDa was detected by Western 
analysis of more than 30 ng of the purified enzyme (not 
shown) or the corresponding amount of Matrex gel red A 
eluate with either rabbit (not shown) or goat-anti-ASM anti- 
serum (Fig. 3), suggesting co-purification of the placental 
homologue to the 57 kDa fibroblast form of ASM. Another 
band at ~48 kDa probably represented the deglycosylated 
product (not shown). The 57 kDa protein was not visible in 
Figs. 1 and 2, but as a faint band in Fig. 3, suggesting an 
amount < 5% of the total placental ASM. Further character- 
ization of this protein was hampered by its low abundance. 
The purified enzyme showed maximal activity at pH 4,6- 
4.7, with half maximal activity at pH 3.7 3.8 and pH 5.9-6. 
No ASM activity was observed below pH 3.1 and above pH 
7.5 (not shown). The kinetic properties of the purified ASM 
were assessed using sphingomyelin asthe substrate in a deter- 
gent-containing assay system (Fig. 4). The enzymatic hydro- 
lysis of sphingomyelin followed Michaelis-Menten kinetics. 
The K,,l and the V,n~× value were calculated to be ,-~ 25 ~M 
and ,-~ 1.3 mmol/h per mg protein, respectively. Isoelectric 
focusing of the purified ASM resulted in a broad major 
peak of activity at pI 6.5 and a minor one at pl 7.5 (not 
shown). 
4. Discussion 
The purification of human placental ASM, as reported here, 
Fable 1 
Purification of ASM from human placenta (1.5 kg) 
Purification step Total protein Total activity Specific activity Yield Enrichment (-fold) 
(rag) (gmol/h) (~amol h ling l) (%) 
Crude extract 102 560 923 0.009 100 l 
30-60% (NH4)2SO4 fractionation 34210 582 0.017 63 2 
Con A-Sepharose 586 421.8 0.72 46 80 
Octyl-Sepharose 89 277.6 3.12 30 347 
Matrex gel red A 6.57 143.1 21.78 15.5 2 420 
lmmunoaffinity chromatography a 0.008 ~' 8.1 ~' 1 012.5 0.9 112 500 
~Only 50% of the total activity of the Matrex gel red A eluate was subjected to immunoaffinity chromatography. 
bThe total enzyme activity and total amount of protein of the concentrated luate are shown. 
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yields an apparently homogeneous enzyme preparation as 
judged by SDS-PAGE followed by silver staining (Fig. 1) 
with a specific activity of ,-~1 mmol h -1 mg -1. The 
,~ 110000-fold increase in specific ASM activity achieved by 
our protocol is higher than the purification factors described 
in previous procedures starting from human placenta, indicat- 
ing inhomogeneous ASM preparations (,~33000-fold, spec. 
act. ,~0.38 mmol h -1 mg -1 [5]; ,~20000-fold, spec. act. 
,~0.1-0.15 mmol h -1 mg -1 [26]). 
Previous reports on ASM purification from other sources 
also resulted in significantly lower purification factors, 
whereas the specific activity was close to that of our prepara- 
tion (urinary ASM: ,~ 23 000-fold, spec. act. ~ 2.5 mmol h -1 
mg -1 [7]; brain ASM: ,~21 000-fold, spec. act. ~0.8 mmol 
h -1 mg -1 [4]). The differences in the enrichment factors might 
be due to the greater specific ASM activity described in hu- 
man urine and in human brain extract. 
In this report we present, for the first time, the N-terminal 
amino acid sequence (H2N-GlyS3-Trp-Gly-Asn-Leu-Thr-Cys - 
Pro-...) of human mature lysosomal ASM. This reveals that 
final proteolytic processing of the ASM precursor to the ma- 
ture lysosomal enzyme occurs between the amino acid resi- 
dues Phe 82 and Gly s3, three residues in the N-terminal direc- 
tion from the first potential N-glycosylation site. This 
indicates that all six potential glycosylation sites are present 
on the mature placental enzyme. Removal of the signal pep- 
tide (presumably residues 1-46 [27]) and an N-terminal seg- 
ment of 36 additional amino acids seems to be the major 
proteolytic processing events occurring on the monomeric 
ASM precursor. 
The maximal possible size of the protein core of mature 
ASM, assuming no C-terminal proteolytic processing, is cal- 
culated to be 61 077 Da using the ExPASy Molecular Biology 
Server. This theoretical molecular mass agrees well with the 
experimental data of ,,~ 60 kDa. Complete deglycosylation f 
the enzyme led to molecular mass reduction by ,~ 15 kDa, 
indicating that most of the six potential N-glycosylation sites 
are utilized in vivo. The molecular mass of placental ASM 
appeared to be slightly higher than that for the urinary and 
the fibroblast enzyme [7,19]. After complete deglycosylation 
all enzymes howed the same molecular mass of ,-~ 60 kDa, 
2 3 
kDa 
- -  97  
- -  66  
- -  46  
30  
Fig. 3. Immunodetection of ASM at different stages of purification. 
Concanavalin A-Sepharose, octyl-Sepharose and Matrex gel red A 
eluate were separated by non-reducing 10% SDS-PAGE electro- 
blotted onto PVDF membrane. ASM was detected using polyclonal 
goat-anti-ASM antiserum (dilution 1:1000). Lanes: (1) Matrex gel 
red A eluate; (2) octyl-Sepharose eluate; (3) Concanavalin A-Se- 
pharose luate (ASM/lane: ~ 30 ng, each). 
E 
E 
E 
..=. 
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Fig. 4. Kinetic analysis of purified ASM. Purified ASM was incu- 
bated for 0.5 h at 37°C with increasing amounts of sphingomyelin 
in the presence of NP-40. Each assay contained: ~ 1.4 ng of puri- 
fied ASM, [3H]choline-labeled sphingomyelin (5-200 ~M), 0.1% (w/ 
v) NP-40 and 250 mM sodium acetate buffer, pH 4.8, in a total vo- 
lume of 50 p.l. The relationship of ASM activity values to the corre- 
sponding substrate concentrations is shown in the form of a double- 
reciprocal plot according to Lineweaver and Burk [26]. 
suggesting that these differences might be due to variable car- 
bohydrate processing events. 
Besides the major band at ,~ 75 kDa, representing mature 
lysosomal ASM, a faint band at ,~ 57 kDa was immunode- 
tected in Matrex gel red A eluate and in the final ASM pre- 
paration (-~30 ng enzyme). This band possibly corresponds to
the 57 kDa ASM form recently described in human fibroblasts 
and transfected COS cells [19,20]. This assumption is sup- 
ported by the observation that complete deglycosylation 
seems to reduce its molecular mass to ,-~ 48 kDa, similar to 
the 57 kDa fibroblast form. However, a slow proteolytic 
cleavage of the mature ASM during purification, yielding 
the 57 kDa protein, cannot be excluded. 
In summary, we have isolated apparently homogeneous pla- 
cental lysosomal ASM using an efficient immunoaffinity-based 
purification procedure. We have characterized the pure en- 
zyme and present for the first time the N-terminal amino 
acid sequence of mature mammalian ASM. 
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